Cancer Therapy

Experimental Drug Inhibits Corneal Angiogenesis And Tumor Growth

Published in Cancer Weekly, September 11th, 2001

by Sonia Nichols, senior medical writer - Tests of a new tubulin-binding drug called BTO-956 show it inhibits both growth factor-induced corneal angiogenesis and the growth of rodent cancer cells.

Duke University researchers in North Carolina, joined by colleagues at SRI International in Menlo Park, California, have performed rodent model experiments suggesting BTO-956 is a potent angiogenesis inhibitor. The drug has already been shown to affect human breast and ovarian cancer tumor growth in murine model studies.

In a first phase of the new experiments, Siqing Shan and colleagues, Duke University, Durham, implanted pellets containing the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry